 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Early experience with Puerto Rico: Effective use management of bone agents. (Pubmed Central) - Feb 6, 2017
Oncology Analytics presence in a new market enhances cancer care quality and cancer care value quickly, while at the same time conserving substantial resources.
- || zoledronic acid / Generic mfg.
Enrollment change, Adverse events: Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=2560, Active, not recruiting, Sponsor: Amgen
Oncology Analytics presence in a new market enhances cancer care quality and cancer care value quickly, while at the same time conserving substantial resources. N=2100 --> 2560
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP (clinicaltrials.gov) - Feb 2, 2017
P2b, N=41, Recruiting, Sponsor: Elizabeth Shane
N=2100 --> 2560 Initiation date: Aug 2014 --> Nov 2014
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: DOHA: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis (clinicaltrials.gov) - Feb 2, 2017
P3, N=20, Not yet recruiting, Sponsor: Hamad Medical Corporation
- | Prolia (denosumab) / Amgen
New P2 trial: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury (clinicaltrials.gov) - Jan 24, 2017
P2, N=32, Not yet recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab and Male Infertility: a RCT (clinicaltrials.gov) - Jan 24, 2017
P2, N=95, Not yet recruiting, Sponsor: Martin Blomberg Jensen
- || Prolia (denosumab) / Amgen
New P3 trial: DENOCINA: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. (clinicaltrials.gov) - Jan 23, 2017
P3, N=60, Not yet recruiting, Sponsor: Peter Vestergaard
- ||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jan 10, 2017
P3, N=7180, Completed, Sponsor: Amgen
Initiation date: Aug 2014 --> Nov 2014 Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Denosumab Versus Bisphosphonates (Alendronate) in GIOP (clinicaltrials.gov) - Dec 28, 2016
P4, N=220, Not yet recruiting, Sponsor: Tuen Mun Hospital
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Study of Denosumab in Subjects With Giant Cell Tumor of Bone (clinicaltrials.gov) - Dec 19, 2016
P2, N=536, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Initiation date: Jun 2008 --> Sep 2008
- | Prolia (denosumab) / Amgen
Phase classification: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Dec 19, 2016
P4, N=575462, Active, not recruiting, Sponsor: Amgen
Initiation date: Jun 2008 --> Sep 2008 Phase classification: P=N/A --> P4
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial, Surgery: GCTLIMBS: Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=412, Completed, Sponsor: Istituto Ortopedico Rizzoli
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Phase classification: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia (clinicaltrials.gov) - Dec 12, 2016
P4, N=777, Active, not recruiting, Sponsor: Amgen
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer (clinicaltrials.gov) - Dec 2, 2016
P3, N=129, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4 Trial primary completion date: Dec 2016 --> Dec 2017
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis (clinicaltrials.gov) - Dec 1, 2016
P2, N=90, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Feb 2016 --> Dec 2016
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Enrollment change, Trial primary completion date: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (clinicaltrials.gov) - Dec 1, 2016
P4, N=26, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Completed | N=40 --> 26 | Trial primary completion date: Dec 2014 --> Apr 2014
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Denosumab and Teriparatide Study (DATA-HD and DATA-EX) (clinicaltrials.gov) - Dec 1, 2016
P4, N=76, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=40 --> 26 | Trial primary completion date: Dec 2014 --> Apr 2014 Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study (clinicaltrials.gov) - Nov 28, 2016
P2, N=20, Recruiting, Sponsor: Children's Hospital of Eastern Ontario
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: DIBLAN: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa (clinicaltrials.gov) - Nov 21, 2016
P3, N=84, Recruiting, Sponsor: University Hospital, Montpellier
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, IO biomarker: Presurgical Trial of Denosumab in Breast Cancer (clinicaltrials.gov) - Nov 18, 2016
P0, N=35, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen
Enrollment closed, IO biomarker: D-Beyond: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (clinicaltrials.gov) - Oct 28, 2016
P2, N=39, Active, not recruiting, Sponsor: Jules Bordet Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change, HEOR: Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=236, Not yet recruiting, Sponsor: Shaare Zedek Medical Center
Recruiting --> Active, not recruiting N=360 --> 236
- |||| Prolia (denosumab) / Amgen
Trial primary completion date: Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) (clinicaltrials.gov) - Oct 20, 2016
P3, N=4509, Active, not recruiting, Sponsor: Amgen
N=360 --> 236 Trial primary completion date: Nov 2017 --> Aug 2017
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=500, Recruiting, Sponsor: Tomidahama Hospital
Trial primary completion date: Nov 2017 --> Aug 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date, IO biomarker: Presurgical Trial of Denosumab in Breast Cancer (clinicaltrials.gov) - Oct 16, 2016
P0, N=35, Not yet recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Nov 2016 --> Nov 2017 Initiation date: Sep 2016 --> Dec 2016
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date, Trial primary completion date: Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children (clinicaltrials.gov) - Oct 13, 2016
P1, N=12, Not yet recruiting, Sponsor: St. Justine's Hospital
Initiation date: Sep 2016 --> Dec 2016 Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Mar 2022 --> Oct 2022
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Trial initiation date: REaCT-BTA: 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (clinicaltrials.gov) - Sep 28, 2016
P4, N=250, Recruiting, Sponsor: Ottawa Hospital Research Institute
Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Mar 2022 --> Oct 2022 Initiation date: Mar 2016 --> Aug 2016 | Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions (clinicaltrials.gov) - Sep 16, 2016
P2, N=20, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial, IO biomarker: Presurgical Trial of Denosumab in Breast Cancer (clinicaltrials.gov) - Sep 14, 2016
P0, N=35, Not yet recruiting, Sponsor: New York University School of Medicine
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=86, Completed, Sponsor: HealthEast Care System
Initiation date: Mar 2016 --> Aug 2016 | Not yet recruiting --> Recruiting Recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients (clinicaltrials.gov) - Aug 3, 2016
P4, N=32, Completed, Sponsor: Stanley Dudrick's Memorial Hospital
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study (clinicaltrials.gov) - Jul 27, 2016
P2, N=20, Not yet recruiting, Sponsor: Children's Hospital of Eastern Ontario
Recruiting --> Completed Initiation date: Mar 2016 --> Oct 2016
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (clinicaltrials.gov) - Jul 19, 2016
P4, N=90, Recruiting, Sponsor: 424 General Military Hospital
Initiation date: Mar 2016 --> Oct 2016 Trial primary completion date: Jul 2018 --> Jul 2019
- ||||| Prolia (denosumab) / Amgen
New P2 trial: A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency (clinicaltrials.gov) - Jul 14, 2016
P2, N=55, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Prolia (denosumab) / Amgen, Kineret (anakinra) / SOBI
Trial primary completion date, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Jun 29, 2016
P1, N=147, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Jun 2017 --> Jun 2019
- || Prolia (denosumab) / Amgen
Trial primary completion date, Combination therapy, Metastases: Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 24, 2016
P2, N=226, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2017 --> Jun 2019 Trial primary completion date: Nov 2016 --> Jul 2016
- Prolia (denosumab) / Amgen
Enrollment open: PROUD: Preventing Osteoporosis Using Denosumab (clinicaltrials.gov) - Jun 24, 2016
P4, N=212, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Nov 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (clinicaltrials.gov) - Jun 22, 2016
P3, N=795, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2016
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Metastases: Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss (clinicaltrials.gov) - Jun 15, 2016
P3, N=760, Completed, Sponsor: Amgen
Trial primary completion date: Jun 2017 --> Jun 2016 Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: HDENO: Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease (clinicaltrials.gov) - Jun 9, 2016
P4, N=30, Not yet recruiting, Sponsor: University Hospital, Montpellier
- ||||| Prolia (denosumab) / Amgen
Enrollment closed: Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma (clinicaltrials.gov) - May 21, 2016
P3, N=1718, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Enrollment closed, Trial primary completion date, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=45, Active, not recruiting, Sponsor: Hope Rugo, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2015
- ||||| Prolia (denosumab) / Amgen
New P2 trial: RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints (clinicaltrials.gov) - May 13, 2016
P2, N=100, Recruiting, Sponsor: University Hospital, Ghent
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: EDRPBLFHR: Longjohn Amgen Study - Effect of Denosumab... (clinicaltrials.gov) - May 12, 2016
P=N/A, N=80, Not yet recruiting, Sponsor: University of Southern California
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2015 Initiation date: Jul 2015 --> Jun 2016
- | Prolia (denosumab) / Amgen
New P4 trial: The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty (clinicaltrials.gov) - May 4, 2016
P4, N=60, Completed, Sponsor: Fundaci
- Xtandi (enzalutamide) / Pfizer, Astellas, Prolia (denosumab) / Amgen
New trial: Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases (clinicaltrials.gov) - May 2, 2016
P=N/A, N=30, Recruiting, Sponsor: University of Hawaii
- | Prolia (denosumab) / Amgen
New P4 trial: PROUD: Preventing Osteoporosis Using Denosumab (clinicaltrials.gov) - Apr 27, 2016
P4, N=212, Not yet recruiting, Sponsor: University of Pittsburgh
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: The Relationship Between the Residual Renal Function and Osteoporosis Treatment (clinicaltrials.gov) - Apr 22, 2016
P=N/A, N=1000, Recruiting, Sponsor: Toshihiko Kono
Initiation date: Jul 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Dec 2018
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Study of Denosumab in Subjects With Giant Cell Tumor of Bone (clinicaltrials.gov) - Apr 21, 2016
P2, N=530, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Dec 2018 Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: DIBLAN: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa (clinicaltrials.gov) - Apr 20, 2016
P3, N=84, Not yet recruiting, Sponsor: University Hospital, Montpellier
Recruiting --> Active, not recruiting Initiation date: Dec 2015 --> May 2016